Medical Oncology Market By Cancer Diagnostics & Treatment (Cancer diagnostics, Cancer treatment) By Cancer Type (Lung cancer, Prostate cancer, Colon & rectal cancer, Gastric cancer, Esophageal cancer, Liver cancer, Breast cancer, Others), By End-use (Hospitals, Diagnostic laboratories, Diagnostic imaging centers, Academia, Specialty clinics, Others) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Medical Oncology Market Size was valued at USD 356.2 billion in 2022 and is poised to grow at a CAGR of 8.6% from 2023-2029. Cancer is one of the main causes of mortality worldwide, and the number of cancer patients grows every year. Every year, more than 10.6 million people worldwide die from cancer. The global oncology market is experiencing tremendous growth in demand for cancer diagnosis and treatment, and there are numerous new advancements in this sector that are promising novel cancer treatments and cures. As the number of cancer patients grows, so does the demand for cancer diagnosis and therapy. Over the next 20 years, an estimated 43 million new cases of cancer will be diagnosed in the United States, with approximately 24 million people dying from the disease. One reason why the oncology industry is growing is that more people are being diagnosed with cancer at an earlier stage. According to the American Cancer Society (ACS), over one-third of all malignancies are now detected at an early stage, allowing for better treatment options and a higher chance of survival. CT scans is an important technique that has aided in the early diagnosis of cancer. They are frequently used to detect malignancies in the lungs, liver, and other organs. CT scans are also being used increasingly regularly to screen for breast and other types of cancer. The results of a CT scan can help doctors determine if someone should have further tests or if they have a tumor in the oncology market. Moreover, rise in various government and non-government initiatives, for instance in India States/UTs (with Legislature) have set up Illness Assistance Fund that offers coverage up to Indian rupees 1 Lakh for cancer treatment. In addition, there are other policies like National Program for Prevention and Control of Cancer, Diabetes Care Devices, Cardiovascular Diseases and Stroke (NPCDCS). This type of policies helping patient to get their treatment. Furthermore, oncology treatment side effects, such as chemotherapy, have the potential to stifle global medical oncology growth. Chemotherapy patients may suffer long-term harm to their hearts, lungs, kidneys, or reproductive functions. This can happen after the therapy by harming healthy cells, impeding the industry's progress. Furthermore, several chemotherapy medicines may induce delayed adverse effects. Among the most prevalent side effects include hair loss, weariness, anemia, infections, and easy bruising and bleeding, all of which hampering the overall market demand.

Medical Oncology Market Key Developments:
  • In July 2021, AstraZeneca announced that their medicine Imfinzi has been approved for the treatment of patients with non-small cell lung cancer by China's National Medical Products Administration.
  • In June 2021, Bayer AG has announced an agreement to buy Noria Therapeutics Inc. and PSMA Therapeutics Inc. Bayer will obtain exclusive rights to the company's experimental substance under this agreement. This acquisition will aid Bayer's cancer portfolio expansion.

Medical Oncology Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.6%

Largest Market

Asia Pacific

Fastest Growing Market

North America
Medical Oncology Market Dynamics

The rising prevalence of cancer disease and the occurrence of various cancer conditions, as well as the popularity of advanced therapies (biological and targeted pharmacological therapies), are propelling the global oncology/cancer market. Furthermore, increased cancer awareness and early cancer detection help to propel the oncology medication industry forward. However, the high costs of new drug development, as well as the risk of failure and adverse effects associated with cancer drug therapies, are limiting the market's growth. In contrast, the high potential of emerging economies, as well as the increased number of potential drugs in the pipeline, are expected to provide profitable opportunities during the forecast period.

Medical Oncology Market Segmentation

By Cancer diagnostics
  • Cancer diagnostics
  • Cancer treatment
By Cancer Type
  • Lung cancer
  • Prostate cancer
  • Colon & rectal cancer
  • Gastric cancer
  • Esophageal cancer
  • Liver cancer
  • Breast cancer
  • Others
By End User
  • Hospitals
  • Diagnostic laboratories
  • Diagnostic imaging centers
  • Academia
  • Specialty clinics
  • Others
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA
LOCATION

Geography

Frequently Asked Questions

The increasing prevalence of cancers and presence of strong pipeline candidates are major factors driving the growth of the market.

New product launch, agreement, collaboration, acquisition, partnership, and product approval are the key trends in the medical Oncology market report.

Major players across the industry comprise Bayer AG, GE Healthcare, Thermo Fischer Scientific, Abbott, Janssen Diagnostics, LLC, Merck, Pfizer, F. Hoffmann-La Roche, and others.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
1. Executive Summary
2. Global Medical Oncology Market Introduction
2.1. Global Medical Oncology Market – Taxonomy
2.2. Global Medical Oncology Market – Definitions
2.2.1. Cancer Diagnostics & Treatment
2.2.2. Cancer Type
2.2.3. End User
2.2.4. Region
3. Global Medical Oncology Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Medical Oncology Market Dynamic Factors - Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Epidemiology
3.8. Three Forecast Scenarios - Pessimistic, Conservative and Opportunistic
3.9. Mapping Market Players Activities
3.10. Recent Key Developments
3.11. Financial Status of the Market Players
3.12. Recent Acquisitions, Collaborations and Mergers
4. Global Medical Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Medical Oncology Market Forecast, By Cancer Diagnostics & Treatment, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.1. Cancer diagnostics
5.1.1. Tumor Biomarkers Test
5.1.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Imaging
5.1.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Biopsy
5.1.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Liquid Biopsy
5.1.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Immunohistochemistry
5.1.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.1.6. In Situ Hybridization
5.1.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.6.3. Market Opportunity Analysis
5.2. Cancer treatment
5.2.1. Chemotherapy
5.2.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Targeted therapy
5.2.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Immunotherapy
5.2.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Hormonal therapy
5.2.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
5.2.5. Others
5.2.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.5.3. Market Opportunity Analysis
6. Global Medical Oncology Market Forecast, By Cancer Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
6.1. Lung cancer
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Prostate cancer
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Colon & rectal cancer
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Gastric cancer
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Esophageal cancer
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Liver cancer
6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Breast cancer
6.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Others
6.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
7. Global Medical Oncology Market Forecast, By End User, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Diagnostic laboratories
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3.   Diagnostic imaging centers
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Academia
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Specialty clinics
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. others
7.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
8. Global Medical Oncology Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Medical Oncology Market - Opportunity Analysis Index, By Cancer Diagnostics & Treatment, Cancer Type, End User, and Region, 2023 - 2029
9. North America Medical Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
9.1. Cancer Diagnostics & Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Cancer diagnostics
9.1.1.1. Tumor Biomarkers Test
9.1.1.2. Imaging
9.1.1.3. Biopsy
9.1.1.4. Liquid Biopsy
9.1.1.5. Immunohistochemistry
9.1.1.6. In Situ Hybridization
9.1.2. Cancer treatment
9.1.2.1. Chemotherapy
9.1.2.2. Targeted therapy
9.1.2.3. Immunotherapy
9.1.2.4. Hormonal therapy
9.1.2.5. Others
9.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Lung cancer
9.2.2. Prostate cancer
9.2.3. Colon & rectal cancer
9.2.4. Gastric cancer
9.2.5. Esophageal cancer
9.2.6. Liver cancer
9.2.7. Breast cancer
9.2.8. Others
9.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospitals
9.3.2. Diagnostic laboratories
9.3.3. Diagnostic imaging centers
9.3.4. Academia
9.3.5. Specialty clinics
9.3.6. Others
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Medical Oncology Market - Opportunity Analysis Index, By Cancer Diagnostics & Treatment, Cancer Type and Country, 2023 - 2029
9.6. North America Medical Oncology Market Dynamics – Trends
10. Europe Medical Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
10.1. Cancer Diagnostics & Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Cancer diagnostics
10.1.1.1. Tumor Biomarkers Test
10.1.1.2. Imaging
10.1.1.3. Biopsy
10.1.1.4. Liquid Biopsy
10.1.1.5. Immunohistochemistry
10.1.1.6. In Situ Hybridization
10.1.2. Cancer treatment
10.1.2.1. Chemotherapy
10.1.2.2. Targeted therapy
10.1.2.3. Immunotherapy
10.1.2.4. Hormonal therapy
10.1.2.5. Others
10.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Lung cancer
10.2.2. Prostate cancer
10.2.3. Colon & rectal cancer
10.2.4. Gastric cancer
10.2.5. Esophageal cancer
10.2.6. Liver cancer
10.2.7. Breast cancer
10.2.8. Others
10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospitals
10.3.2. Diagnostic laboratories
10.3.3. Diagnostic imaging centers
10.3.4. Academia
10.3.5. Specialty clinics
10.3.6. Others
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Medical Oncology Market - Opportunity Analysis Index, By Cancer Diagnostics & Treatment, Cancer Type and Country, 2023 - 2029
10.6. Europe Medical Oncology Market Dynamics – Trends
11. Asia-Pacific Medical Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
11.1. Cancer Diagnostics & Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Cancer diagnostics
11.1.1.1. Tumor Biomarkers Test
11.1.1.2. Imaging
11.1.1.3. Biopsy
11.1.1.4. Liquid Biopsy
11.1.1.5. Immunohistochemistry
11.1.1.6. In Situ Hybridization
11.1.2. Cancer treatment
11.1.2.1. Chemotherapy
11.1.2.2. Targeted therapy
11.1.2.3. Immunotherapy
11.1.2.4. Hormonal therapy
11.1.2.5. Others
11.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Lung cancer
11.2.2. Prostate cancer
11.2.3. Colon & rectal cancer
11.2.4. Gastric cancer
11.2.5. Esophageal cancer
11.2.6. Liver cancer
11.2.7. Breast cancer
11.2.8. Others
11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospitals
11.3.2. Diagnostic laboratories
11.3.3. Diagnostic imaging centers
11.3.4. Academia
11.3.5. Specialty clinics
11.3.6. Others
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Rest of Asia-Pacific
11.5. Asia-Pacific Medical Oncology Market - Opportunity Analysis Index, By Cancer Diagnostics & Treatment, Cancer Type and Country, 2023 - 2029
11.6. Asia-Pacific Medical Oncology Market Dynamics – Trends
12. Latin America Medical Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
12.1. Cancer Diagnostics & Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Cancer diagnostics
12.1.1.1. Tumor Biomarkers Test
12.1.1.2. Imaging
12.1.1.3. Biopsy
12.1.1.4. Liquid Biopsy
12.1.1.5. Immunohistochemistry
12.1.1.6. In Situ Hybridization
12.1.2. Cancer treatment
12.1.2.1. Chemotherapy
12.1.2.2. Targeted therapy
12.1.2.3. Immunotherapy
12.1.2.4. Hormonal therapy
12.1.2.5. Others
12.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Lung cancer
12.2.2. Prostate cancer
12.2.3. Colon & rectal cancer
12.2.4. Gastric cancer
12.2.5. Esophageal cancer
12.2.6. Liver cancer
12.2.7. Breast cancer
12.2.8. Others
12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospitals
12.3.2. Diagnostic laboratories
12.3.3. Diagnostic imaging centers
12.3.4. Academia
12.3.5. Specialty clinics
12.3.6. Others
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Rest of Latin America
12.5. Latin America Medical Oncology Market - Opportunity Analysis Index, By Cancer Diagnostics & Treatment, Cancer Type and Country, 2023 - 2029
12.6. Latin America Medical Oncology Market Dynamics – Trends
13. Middle East and Africa Medical Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Million)
13.1. Cancer Diagnostics & Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Cancer diagnostics
13.1.1.1. Tumor Biomarkers Test
13.1.1.2. Imaging
13.1.1.3. Biopsy
13.1.1.4. Liquid Biopsy
13.1.1.5. Immunohistochemistry
13.1.1.6. In Situ Hybridization
13.1.2. Cancer treatment
13.1.2.1. Chemotherapy
13.1.2.2. Targeted therapy
13.1.2.3. Immunotherapy
13.1.2.4. Hormonal therapy
13.1.2.5. Others
13.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Lung cancer
13.2.2. Prostate cancer
13.2.3. Colon & rectal cancer
13.2.4. Gastric cancer
13.2.5. Esophageal cancer
13.2.6. Liver cancer
13.2.7. Breast cancer
13.2.8. Others
13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospitals
13.3.2. Diagnostic laboratories
13.3.3. Diagnostic imaging centers
13.3.4. Academia
13.3.5. Specialty clinics
13.3.6. Others
13.4. MEA Medical Oncology Market - Opportunity Analysis Index, By Cancer Diagnostics & Treatment, Cancer Type and Country, 2023 - 2029
13.5. MEA Medical Oncology Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Cancer Diagnostics & Treatment Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Aegerion Pharmaceuticals Inc.
14.2.2. Abbvie Inc.
14.2.3. Ability Pharma
14.2.4. Acadia Pharmaceuticals Inc.
14.2.5. Amgen Inc.
14.2.6. Takeda Oncology
14.2.7. Aslan Pharmaceuticals Ltd.
14.2.8. Aspen Pharmacare Holdings Limited.
14.2.9. Astrazeneca
14.2.10. Athenex, Inc.
15. Research Methodology
16. Key Assumptions and Acronyms
  • Aegerion Pharmaceuticals Inc.
  • Abbvie Inc.
  • Ability Pharma
  • Acadia Pharmaceuticals Inc.
  • Amgen Inc.
  • Takeda Oncology
  • Aslan Pharmaceuticals Ltd.
  • Aspen Pharmacare Holdings Limited.
  • Astrazeneca
  • Athenex, Inc.

Adjacent Markets